Dr. Li is a portfolio manager and director of research – China at Causeway. He is also general manager of Causeway (Shanghai) Information Consulting Co., Ltd., a wholly foreign owned subsidiary of Causeway Capital Management LLC (“WFOE”). He joined Causeway in July 2012 and became a US portfolio manager in January 2021, where he has responsibilities for Causeway’s China equity strategy that launched in March 2021. He became an employee at the WFOE in January 2021. Dr. Li currently oversees research of companies in China. His previous responsibilities included coverage of companies in the healthcare and TMT sectors as well as companies in the China region.

From August to October 2011, Dr. Li was an equity research intern at Legg Mason Capital Management where he was responsible for the coverage of US healthcare and consumer sectors. From January to May 2011, Dr. Li worked as a part time equity research intern at Legg Mason Capital Management where he was responsible for the coverage of the healthcare industry in China. During the summer of 2011, Dr. Li worked as a research and early development project finance intern for Genentech Inc. Dr. Li worked on a health sector management practicum at Stryker Corporation from January through May of 2011. From 2007 to 2010, Dr. Li worked as a postdoctoral researcher and teaching fellow at the University of California, San Francisco where he initiated and led a research project on a novel cancer treatment while teaching cancer biology classes. From 2004 to 2007, Dr. Li was the founder and president of Lee Proteome Research Laboratory where he led a team that analyzed biotechnology business opportunities. Dr. Li was a postdoctoral researcher from 2003 to 2006 at the University of Pennsylvania.

Dr. Li earned a PhD in pharmacology from the University of Pennsylvania, an MBA, with honors, from Duke University, a Bachelor of Medicine from China Medical University, and an MS in pathology from Peking Union Medical College. Dr. Li is a CFA charterholder.

Read our profile of Fusheng and his approach to investing in China.